Raul Cordoba: Early progression beyond first-line chemoimmunotherapy in follicular lymphoma by Alberto Bavieri et al.
Raul Cordoba, Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit, shared a post on X:
“Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study – Bavieri – 2024.”
Authors: Alberto Bavieri et al.
Raúl Córdoba Mascuñano, MD, PhD is a specialist in hematology and hemotherapy. He is the Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit and Associate Chief of Hematology Department at Jiménez Díaz Foundation.
He is the principal investigator for numerous clinical trials for non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia and other chronic lymphoproliferative syndromes. He is a member of the ethical review board at his current workplace.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023